Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer
“On behalf of our executive chairman Dr. Deborah Rathjen, our board of directors and our management team, it is my pleasure to welcome Christine to Bioasis. Christine has a proven track record in finance, including financing transactions, business development, strategic planning and guiding companies through significant growth. Her contributions will be critical as we work to strengthen the company’s market profile and continue to execute on our mission to advance our internal pipeline and license our proprietary xB3 platform technology,” said Mark Day, Ph.D., director, president and chief executive officer. “Christine’s integrity, people skills and strong work ethic have also demonstrated an excellent cultural fit with Bioasis, which will be key as she builds relationships with our board, management team and strategic partners, who share a strong belief in our ability to develop innovative medicines for the treatment of serious neurological diseases, including brain cancers.”
Antalik has previously worked at a number of life sciences companies and brings diverse financial management experience in executing the strategic and financial plans of emerging companies with consistent successes in improving the performance and value of companies.
“I am delighted to join Bioasis at a time when the company is preparing to reach major milestones in its development. I look forward to working in collaboration with Deborah, Mark and the management team to put in place a detailed financial roadmap and position the company for its next level of growth,” said Antalik. “I am excited by the potential of the Bioasis xB3 platform technology and admire the team’s focus and vision on bringing transformational therapies to patients with brain cancers and neurological diseases. I look forward to being part of Bioasis’ bright future and supporting its mission.”
About Christine Antalik
Christine Antalik has more than 25 years of experience in accounting and finance including several high-profile, executive-level roles as chief financial officer. Over the course of her illustrious career, Antalik has closed over $800 million in deal transactions through initial public offerings, private and venture equity financings, debt financings, recapitalizations, research grants and mergers and acquisitions. With four consecutive exits over eleven years, she has an impeccable track record of starting, building, growing and improving the profitability, performance and value of companies, while positioning them for the next level of growth or exit.
Antalik is the managing member of Founders Bridge Advisors, LLC, a business advisory firm located in Connecticut, and has served as chief financial officer of Aeromics, Inc. since October 2016. Previously, Antalik served as chief financial officer of SurgiQuest, Inc. where she led the $265 million acquisition of SurgiQuest, Inc. by CONMED Corporation after filing the company’s public S-1 statement. Antalik closed a $108 million initial public offering as the vice president of finance and controller at HigherOne, Inc., a financial technology company. Prior to HigherOne, Antalik served as controller for Tangoe, Inc., a software service company. As chief financial officer and treasurer of Hematech, LLC, Antalik formed a joint venture with a key services provider to mitigate business risk and ultimately steered the company to a successful exit, being acquired by Kirin Brewery Company, Limited. Antalik also previously served as controller and senior manager of litigation support and business valuation for Centerprise Advisors, Inc. (currently Marcum, LLP), a national consulting and accounting advisory firm, where she provided expert witness reports in economic damages cases, business valuations and forensic accounting services.
Antalik earned her bachelor of science degree in business administration from Western New England College, Springfield, Mass.
As a result of her appointment, the Company has granted Antalik stock options to acquire a total of 95,000 common shares. These options vest over a period of 12 months from the date of the grant, expire five years from the date of the grant and are governed by the terms of the company’s stock option plan. The exercise price of these options will equal the closing price of the Company’s common shares on the TSX Venture Exchange immediately following the expiry of the current “blackout” period under the Company’s insider trading policy as a result of the filing of Bioasis audited financial statements and MD&A for its fiscal year ended Sept. 30, 2018.
Bioasis also advises investors that an updated version of its corporate presentation is available for review on its website at www.bioasis.us/investors.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Mark Day, Ph.D., Director, President & Chief Executive Officer
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, along with other statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward- looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Bioasis Technologies, Inc.
Source: Bioasis Technologies Inc.